Canada markets open in 2 hours 2 minutes

Ayala Pharmaceuticals, Inc. (ADXS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.54000.0000 (0.00%)
At close: 09:41AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.5400
Open0.5400
Bid0.0000 x 3000
Ask0.0000 x 1000
Day's Range0.5400 - 0.5400
52 Week Range0.5000 - 1.9500
Volume271
Avg. Volume22,354
Market Cap23.001M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.5100
Earnings DateMay 21, 2024 - May 27, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

    MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the terms of the sale, Ayala received from Immunome $20 million in cash and 2,175,489 shares of Immunome common stock, and Immunome assumed specified liabilities related to AL102. Ayala may also receive up to an a

  • GlobeNewswire

    Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

    REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 patients were enrolled. ”Completion of enrollment in RINGSIDE represents a significant milestone in the development of AL102,” said Kenneth Berlin, President and Chief Executive Officer of Ayala. “There

  • Business Wire

    Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

    BOTHELL, Wash. & MONMOUTH JUNCTION, N.J., February 06, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, to acquire AL102 and related drug candidate AL101 from Ayala. Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash